Please assess the completion status of the following clinical trial:

Trial Title: Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy participants 1 to 40 years of age at enrollment~* Participants/Parent(s)/Legally authorized representative (LAR) willing to provide written informed consent to participate study voluntarily~* Participants/Parent(s)/LAR who can be followed up during the study period and can comply with the study requirements~Exclusion Criteria:~* Known history of hypersensitivity reactions to other preventive vaccines~* Severe chronic diseases or medical conditions based on the medical judgment of the investigator. In particular, a participant with a) chronic infection such as tuberculosis, or sequel of poliomyelitis, b) known history of immune function disorders, c) chronic use of systemic steroids (\>2 mg/kg/day or \>20 mg/day prednisone equivalent for periods exceeding 10 days)/cytotoxic drugs/immunosuppressants within past 6 weeks, d) active malignancy with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I cancer from which the participant is currently in complete remission, or any other cancer from which the participant has been disease-free for 5 years, e) Congestive heart failure, f) myocardial infarction within the previous 6 months, g) known HIV-infected patients, h) neurological and/or psychiatric disorder, or i) known history of uncontrolled coagulopathy or blood disorders~* Participant who planned to or has received other vaccines from 1 month prior to test vaccination excluding a public health vaccination campaign due to an outbreak~* Participant concomitantly enrolled or scheduled to be enrolled in another trial~* Receipt of blood or blood-derived products in the past 3 months~* Participant who has previously received a cholera vaccine~* Any female participant who is lactating, pregnant or planning for pregnancy during study period~* Participants planning to move from the study area before the end of study period~* Employees or the family members of the OCV-S study sites~Temporary Contraindication:~Should a participant have one of the conditions/situations listed below, the Investigator will postpone primary or subsequent vaccination until the condition/situation is resolved.~* Febrile illness (axillary temperature ≥ 37.5°C) or moderate or severe acute illness/infection on the day of vaccination or planned vaccination, according to Investigator's judgment.~* Gastrointestinal symptoms including nausea, vomiting, or decreased appetite within 24 hours prior to study initiation.~* Administration of antidiarrheal drugs or antibiotics to treat diarrhea or abdominal pain lasting 2 weeks or longer within 6 months prior to study initiation~* Diarrhea occurring up to 1 week within 6 months prior to study initiation.~  * Lactation: Breastfeeding women will not be enrolled. Should a female participant decide to breastfeed during the vaccination period, she will be excluded from further vaccination, but will be followed for safety until the end of the study~ * Pregnancy Test is necessary for all married female participants of childbearing age.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Oral Cholera Vaccine-Simplified (OCV-S) group (Lot 1) (Type: EXPERIMENTAL): Participants (n=330) aged 18-40 years old will received OCV-S (Lot 1) according to 0-2 week schedule.
- Oral Cholera Vaccine-Simplified (OCV-S) group (Lot 2) (Type: EXPERIMENTAL): Participants (n=330) aged 18-40 years old will received OCV-S (Lot 2) according to 0-2 week schedule.
- Oral Cholera Vaccine-Simplified (OCV-S) group (Lot 3) (Type: EXPERIMENTAL): Participants (n=935) aged 1-40 years old will received OCV-S (Lot 3) according to 0-2 week schedule.
- Shanchol™ group (Type: ACTIVE_COMPARATOR): Participants (n=935) aged 1-40 years old will received Shanchol™ according to 0-2 week schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).